E. Buntinx

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

F. Rockhold, Ping Li, G. Siber, 2022, The Lancet.

Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response

C. Nemeroff, A. Schatzberg, T. Schlaepfer, 2011, Psychological Medicine.

Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium

S. Pype, C. De Vos, E. Peeters, 2021, PharmacoEconomics - Open.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents

I. Smolenov, P. López, L. Bravo, 2023, medRxiv.

Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study

Haijing Qin, Ping Li, G. Siber, 2023, Vaccine.